Afatinib (BIBW2992) in HER2-overexpressing Inflammatory Breast Cancer

Condition:   Breast NeoplasmsInterventions:   Drug: Afatinib once daily (OD);   Drug: Vinorelbine WeeklySponsor:   Boehringer IngelheimActive, not recruiting - verified October 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials